Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Amortization of Deferred Charges (2019 - 2020)

NovaBay Pharmaceuticals (NBY) has disclosed Amortization of Deferred Charges for 2 consecutive years, with -$2000.0 as the latest value for Q3 2020.

  • On a quarterly basis, Amortization of Deferred Charges fell 100.85% to -$2000.0 in Q3 2020 year-over-year; TTM through Dec 2021 was -$2000.0, a 101.42% decrease, with the full-year FY2020 number at $141000.0, down 78.96% from a year prior.
  • Amortization of Deferred Charges was -$2000.0 for Q3 2020 at NovaBay Pharmaceuticals, down from $38000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $243000.0 in Q2 2019 to a low of -$2000.0 in Q3 2020.